Eloxatin

Eloxatin is a brand name for oxaliplatin, a platinum-based chemotherapy drug used in the treatment of various cancers. It is a cytotoxic agent that works by interfering with DNA replication and transcription in rapidly dividing cancer cells, ultimately leading to cell death. Eloxatin is commonly employed in combination therapy regimens, particularly for colorectal cancer, where it has shown significant efficacy in both adjuvant and metastatic settings.

The administration of Eloxatin is typically intravenous, and it is often given in cycles as part of a broader treatment plan. Common side effects associated with Eloxatin therapy can include peripheral neuropathy, characterized by tingling, numbness, or pain in the hands and feet, which can be dose-limiting. Other potential side effects may involve gastrointestinal disturbances such as nausea and vomiting, myelosuppression leading to reduced blood cell counts, and fatigue. Careful monitoring by healthcare professionals is essential to manage these side effects and ensure patient safety.

Eloxatin's development marked an advancement in platinum-based chemotherapy, offering an alternative to earlier drugs like cisplatin and carboplatin, particularly for certain types of solid tumors. Its effectiveness is often evaluated based on objective tumor response rates, progression-free survival, and overall survival in clinical trials and patient outcomes. The specific dosage and duration of Eloxatin treatment are determined by oncologists based on the type and stage of cancer, as well as individual patient factors.